Absolutely. Most management teams I've spoken with who are candid about this say they believe it means more than half enrolled. The teams I would consider "excellent" try to have the trial almost completely enrolled or close to it.
It's worth repeating again that Pazdur has no statutory authority in this area. Legislative intent, in fact, argues directly against this desire. But people have learned not to cross him or he'll tie up your drug in limbo until he gets what he wants anyway.
Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr